Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Buys $246,523.38 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc purchased 9,533 shares of Sensei Biotherapeutics stock in a transaction on Monday, March 30th. The shares were purchased at an average cost of $25.86 per share, with a total value of $246,523.38. Following the transaction, the insider owned 145,678 shares in the company, valued at approximately $3,767,233.08. The trade was a 7.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $28.12, for a total value of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.81, for a total value of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.61, for a total value of $23,629.68.
• On Friday, March 27th, Millennium Management Llc acquired 15,321 shares of Sensei Biotherapeutics stock. The stock was bought at an average cost of $26.61 per share, with a total value of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc acquired 5,731 shares of Sensei Biotherapeutics stock. The stock was bought at an average cost of $28.62 per share, with a total value of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total value of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total value of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc acquired 6,175 shares of Sensei Biotherapeutics stock. The stock was bought at an average cost of $34.49 per share, with a total value of $212,975.75.
• On Tuesday, March 31st, Millennium Management Llc acquired 6,005 shares of Sensei Biotherapeutics stock. The stock was bought at an average cost of $28.16 per share, with a total value of $169,100.80.
• On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $32.12, for a total value of $246,231.92.

Sensei Biotherapeutics Stock Up 3.1%

Shares of NASDAQ SNSE traded up $0.61 during trading hours on Friday, hitting $20.43. The company had a trading volume of 40,084 shares, compared to its average volume of 223,112. The stock has a market capitalization of $27.40 million, a P/E ratio of -1.23 and a beta of -0.18. Sensei Biotherapeutics, Inc. has a 1-year low of $5.25 and a 1-year high of $36.76. The firm’s 50 day moving average is $29.11 and its 200-day moving average is $17.85.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings data on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing the consensus estimate of ($0.62) by ($130.83). On average, sell-side analysts predict that Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current year.

Institutional Investors Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC boosted its holdings in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the period. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent filing with the Securities and Exchange Commission. 10.50% of the stock is owned by institutional investors.

Key Stories Impacting Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Analyst Upgrades and Downgrades

SNSE has been the subject of several recent analyst reports. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Leerink Partners assumed coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $40.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.